Evidence map›Paper›PMID 15958635›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2005

In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins.

Hiroshi Fujiwara, J Joseph Melenhorst, Frank El Ouriaghli, Sachiko Kajigaya, Matthias Grube, Giuseppe Sconocchia, Katayoun Rezvani, David A Price, Nancy F Hensel, Daniel C Douek and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Role of B cells as antigen presenting cells.Frontiers in immunology · 2022
    Review
  3. Review
  4. B Cell-Based Cancer Immunotherapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019
    Article
  5. Article
  6. Article
  7. Article
  8. Oncoimmunology · 2015
    Article
  9. Article
  10. Article
  11. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
  12. Article
  13. Tumor vaccines and beyond.Cytotherapy · 2011
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hiroshi FujiwaraStem Cell Allotransplant Section, Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland 20892, USA.
J Joseph Melenhorst
Frank El Ouriaghli
Sachiko Kajigaya
Matthias Grube
Giuseppe Sconocchia
Katayoun Rezvani
David A Price
Nancy F Hensel
Daniel C Douek
A John Barrett
National Heart Lung and Blood Institute · USNational Institute of Allergy and Infectious Diseases · US

Funding

GRAFT-VERSUS-LEUKEMIAZ01HL002342 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI BARRETT, AUSTIN JOHN · 1994 to 2008
$7.7M
Immune ReconstitutionZ01AI005031 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI DOUEK, DANIEL CESAR · 2002 to 2008
$704k
HIV Infection In Vivo And In VitroZ01AI005034 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI DOUEK, DANIEL CESAR · 2002 to 2008
$704k
Intramural NIH HHS Z99 AI999999Medical Research Council G108/441
6 · The paper itself

Abstract

The primary granule proteins (PGP) of myeloid cells are a source of multiple antigens with immunotherapeutic potential for myeloid leukemias. Therefore, we developed a method to induce T-cell responses to PGP protein sequences. We found that gene-transfected antigen-presenting cells efficiently expand functionally competent PGP-specific CD4 and CD8 T cells. The system was optimized using T-cell responses to autologous CD40-activated B cells (CD40-B) transfected with a cytomegalovirus pp65-encoding expression vector. To generate leukemia-specific T cells, expression vectors encoding the PGP proteinase 3 (PR3), human neutrophil elastase, and cathepsin-G were transfected into CD40-B cells to stimulate post-allogeneic stem cell transplantation T cells from five patients with myeloid and three with lymphoid leukemias. T-cell responses to PGP proteinase 3 and human neutrophil elastase were observed in CD8+ and CD4+ T cells only in patients with myeloid leukemias. T-cell responses against cathepsin-G occurred in both myeloid and lymphoblastic leukemias. T cells from a patient with chronic myelogenous leukemia (CML) and from a posttransplant CML patient, expanded against PGP, produced IFN-gamma or were cytotoxic to the patient's CML cells, demonstrating specific antileukemic efficacy. This study emphasizes the clinical potential of PGP for expansion and adoptive transfer of polyclonal leukemia antigen-specific T cells to treat leukemia.

Indexed as

Antigen-Presenting CellsB-LymphocytesCathepsin GCathepsinsCD40 AntigensCD40 LigandCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCells, CulturedGene ExpressionHL-60 CellsHumansInterferon-gammaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, MyeloidLeukocyte ElastaseCathepsin GCathepsinsCD40 AntigensCD40 LigandCTSG protein, humanInterferon-gammaLeukocyte ElastaseMyeloblastinRNA, MessengerSerine Endopeptidases

Identifiers

PMID15958635
PMCPMC2366103
OpenAlexW2114629265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.